Icon

HALAVEN (nda201532)- (1MG/2ML (0.5MG/ML))

ERIBULIN MESYLATE EISAI INC
1MG/2ML (0.5MG/ML)
Yes No
2027-Jul-08 2015-Nov-15
2023-Jan-28 None
None No
HALAVEN is a microtubule inhibitor indicated for the treatment of patients with:  Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.  Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
1 0 1
Total Other Developers 12
Drugs with Suitability No
1MG/2ML (0.5MG/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****** *** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.